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     BSTRACT
In this article, the use of desoxycorticosterone pivalate is retrospectively reviewed in eight 
dogs with primary hypoadrenocorticism, presented at the Small Animal Department of Ghent 
University. The results showed that desoxycorticosterone pivalate provided adequate mineralo-
corticoid replacement in all cases, also in the dogs that had previously been treated with fludro-
cortisone acetate. A starting dosage of 1.5 – 2.2 mg/kg SC was used, with a fixed dosing interval of 
28 days in most of the cases. Each time, prednisolone was added to the therapy as glucocorticoid 
supplementation. No side effects related to desoxycorticosterone pivalate therapy were noted 
and all owners were satisfied with the treatment consisting of desoxycorticosterone pivalate and 
prednisolone. 
SAMENVATTING
In deze retrospectieve studie wordt het gebruik van desoxycorticosterone-pivalaat beschreven 
bij acht honden met primair hypoadrenocorticisme die aangeboden werden op de vakgroep Kleine 
Huisdieren (Faculteit Diergeneeskunde, UGent). Uit de resultaten bleek dat desoxycorticosterone-
pivalaat adequaat was voor de supplementatie van mineralocorticoïden in alle gevallen, ook bij de 
honden die voordien behandeld werden met fludrocortisone-acetaat. Een aanvangsdosis van 1,5 – 2,2 
mg/kg SC werd gegeven met een vast doseringsinterval van 28 dagen in de meeste gevallen. Ter 
supplementatie van de glucocorticoïden werd aan de behandeling telkens prednisolone toegevoegd. Er 
werden geen bijwerkingen gezien die aan desoxycorticosterone-pivalaat konden worden toegeschreven 
en de eigenaren van de honden waren allen tevreden over de behandeling met desoxycorticosterone-
pivalaat en prednisolone. 
A
INTRODUCTION
Canine hypoadrenocorticism (HA), also known as 
Addison’s disease, is an uncommon endocrine disease 
with an overall prevalence of 0.13 to 0.5%, and with 
a higher prevalence in certain breeds (Reusch, 2000; 
Feldman and Nelson, 2004; Hanson et al., 2016). The 
majority of dogs with HA have primary HA, most 
often caused by an immune-mediated lymphocytic 
adrenalitis, resulting in both glucocorticoid (GC) 
and mineralocorticoid (MC) deficiencies (Peterson 
et al., 1996; Feldman and Nelson, 2004). There are 
no pathognomonic signs for HA. Usually, dogs pres-
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ent with a variety of non-specific, waxing and waning 
signs. Most often, these are gastrointestinal in origin, 
such as anorexia, vomiting and diarrhea, sometimes 
with associated blood loss. However, as the disease 
progresses, dogs can present in circulatory shock, i.e. 
acute Addisonian crisis. Azotemia and non-regene-
rative anemia are often noted, although an absent or 
reversed stress leukogram and hyperkalemia, often 
combined with hyponatremia, are more important 
features. A low sodium-to-potassium ratio of less than 
27 to 1 is more specific. These findings, especially the 
abnormal serum electrolyte levels, can raise the sus-
picion of HA. However, an adrenocorticotropic hor-
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mone (ACTH) stimulation test remains mandatory to 
confirm the diagnosis. Serum cortisol concentrations 
below 2 mcg/dL or 50 nmol/L before and one hour 
after ACTH administration are diagnostic (Peterson et 
al., 1996; Feldman and Nelson, 2004; Klein and Pe-
terson, 2010a; Lathan and Thompson, 2018).  
Short-term treatment of dogs with an Addisonian 
crisis includes aggressive intravenous fluid therapy 
with 0.9% saline and the administration of GC. If 
available, short-acting MC are given as well. Long-
term treatment requires lifelong replacement of defi-
cient MC and GC hormones. Fludrocortisone acetate 
(FC), a potent synthetic MC formulation with some 
GC activity, can be used orally at a starting dosage of 
0.01 mg/kg twice daily (Feldman and Nelson, 2004; 
Meeking, 2007; Klein and Peterson, 2010b; Lathan 
and Thompson, 2018). Since 2016, desoxycortico-
sterone pivalate (DOCP) has been registered for the 
treatment of canine HA in most European countries 
by Dechra Pharmaceuticals (Zycortal®, United King-
dom). As DOCP only has MC activity, prednisolone 
must be administered daily. A starting dosage of 
DOCP of 2.2 mg/kg SC every 25 days is suggested  by 
the manufacturer and has been reported by Feldman 
and Nelson (2004). Bates et al. (2013) and Lathan and 
Thompson (2018) have recently proven that lower 
dosages and longer dosing intervals of DOCP are ef-
fective as well. Likewise, at the Post Congress day 
of the European Society of Veterinary Endocrinology 
(ESVE) in Göteborg (2016), it has been suggested to 
use lower dosages at a fixed time interval of 28 days. 
According to Feldman and Nelson (2004), Klein and 
Peterson (2010b) and Lathan and Thomspon (2018), 
follow-up with a physical examination and the mea-
surement of serum electrolyte concentrations should 
be performed 10 days and 25 days post injection, in 
order to determine the need for adjustment of the dos-
age and/or dosing interval. If potassium levels are 
high and/or sodium levels low at day 10, the dose of 
DOCP should be increased by 5 - 15%, whereas the 
dosage interval can be decreased by 1 - 2 days if this 
is noted at day 25 (or 28). If the potassium levels are 
low and/or sodium levels high at day 10, a dose reduc-
tion of 5 - 15% should be performed, and if noted at 
day 25 (or 28) the dosage interval can be prolonged by 
1 - 2 days. This should be carried out until achieving 
stabilization of the DOCP dosage (Klein and Peter-
son, 2010b; Lathan and Thompson, 2018). Once the 
adequate dose and interval have been determined, the 
patient should be monitored twice a year with a physi-
cal examination and serum electrolyte measurement 
(Feldman and Nelson, 2004; Klein and Peterson, 
2010b; Lathan and Thomspon, 2018). With appro-
priate treatment, prognosis is excellent, with normal 
quality of life and life expectancy in more than 80% 
of the treated dogs. However, timely diagnosis and 
treatment are important, as a lacking diagnosis can re-
sult in a fatal Addisonian crisis (Van Zyl and Hyman, 
1994; Meeking, 2007; Klein and Peterson, 2010b; La-
than and Thompson, 2018).
MATERIALS AND METHODS 
Case selection 
Medical records of all dogs diagnosed with pri-
mary HA and treated with DOCP (Zycortal®, Dechra 
Veterinary Products NV, Lille, Belgium) at the Small 
Animal Department of the Faculty of Veterinary Medi- 
cine (Ghent University) between January 2016 and 
September 2017 were reviewed retrospectively. These 
included both newly diagnosed cases and cases that 
were previously treated with FC. Dogs were excluded 
if follow-up, including electrolyte measurement, was 
not available for at least one month.
Procedures 
Signalment, history, physical examination, serum 
electrolyte concentrations, side effects of and response 
to therapy were extracted from the medical files. A 
standardized questionnaire was used to evaluate the 
owner’s opinion concerning costs, number of control 
visits and blood draws, as well as the clinical condi-
tion of their dog during the treatment with DOCP and 
prednisolone.
Objectives
The objective of this retrospective study was to 
give a detailed description of the use of DOCP in a 
series of dogs with primary HA.
RESULTS
Signalment
The median age at presentation was four years 
(range 1 - 9 years). Five out of the eight dogs were 
male. All but one were pedigree dogs, of the follow-
ing breeds: bearded collie, papillon, English cocker 
spaniel, Leonberger, standard poodle, Shih Tzu and 
Irish terrier. 
History, clinical signs and physical examination at 
initial presentation 
Six dogs had been newly diagnosed, of which five 
were emergency cases, presented with an acute Ad-
disonian crisis. Of these five dogs, one dog presented 
with signs of hypovolemic shock, with severe hypoten-
sion and stupor, while the other four expressed signs 
of dehydration. Five newly diagnosed cases presented 
with acute lethargy and anorexia, although this was 
chronic in one new case. Vomiting was noted in four 
of them and polyuria/polydipsia was present in three 
cases. Three of these five dogs also had chronic and 
intermittent complaints, namely lethargy, intermittent 
anorexia, episodic vomiting and diarrhea or polyuria/
polydipsia. The remaining two cases had been receiv-
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ing GC and FC before presentation. Both dogs were 
monitored with frequent clinical controls and measure-
ment of serum electrolyte concentrations. Both were 
switched to GC and DOCP due to insufficient control 
of the disease, manifested by vomiting, anorexia and 
lethargy in one case and persistent GC side effects 
(polyuria/polydipsia, polyphagia and/or poor skin con-
dition) with abnormal electrolyte levels in both cases. 
Laboratory findings at initial presentation  
One dog showed mild regenerative anemia and all 
dogs had an absent or reversed stress leukogram. Five 
dogs had elevated levels of serum urea, of which one 
showed mild azotemia and two more pronounced azo-
temia. One dog was severely hypoglycemic and one 
dog presented with mild hyperalbuminemia. All dogs 
had abnormal serum electrolyte levels, six of which 
showed hyperkalemia and seven hyponatremia. In 
half of the cases, the electrolyte abnormalities were 
severe, with potassium values above 7 mmol/l in four 
and sodium levels below 125 mmol/l in one case (refe- 
rence intervals 3.5 - 5.8 and 144 - 160 mmol/l, respec- 
tively). 
Treatment 
Stabilization and initial treatment with DOCP and 
prednisolone
Both dogs previously treated with FC and one 
other dog were not hospitalized at the time of the first 
DOCP injection. The other five dogs that suffered 
from an Addisonian crisis, were initially stabilized 
with adequate fluid therapy, using 0.9% saline. In four 
cases, IV boli of glucose 50% at 0.5 - 2 g/kg (Glucose 
Sterop 50 mg/ml, Laboratories Sterop, Brussels, Bel-
gium) and in three dogs, short-acting human insulin 
at 0.1 IU/kg (Humuline Regular Cartridge 100 IU/ml, 
Eli Lilly Benelux NV, Brussels, Belgium) were ad-
ministered. As a result, three of the hospitalized dogs 
had normal electrolyte levels at the time of DOCP ad-
ministration, one still had slight abnormalities and in 
one case, it was not remeasured. The starting dosage 
of 2.2 mg/kg SC, as prescribed by the manufacturer, 
was given to six dogs, while two dogs received a low-
er starting dosage of 1.5 mg/kg SC. All dogs had nor-
mal serum electrolyte levels ten days after the DOCP 
injection, although one dog showed borderline hyper-
kalemia. Prednisolone was also administered to all 
dogs, at a dosage of 0.11 - 0.5 mg/kg/day PO, which 
in all but two cases was divided over two gifts. Both 
dogs that were switched to DOCP, had a doubling of 
the previously given dosage of prednisolone. Clinical 
signs resolved in all dogs within ten days. 
Second injection with DOCP 
From the six dogs that were started on 2.2 mg/kg 
DOCP, three had a subsequent 10% decrease in 
DOCP dosage, while a larger dose reduction of 20% 
was performed in the two other dogs. According to 
the guidelines of the manufacturer (Table 1), this re-
duction was based on the sodium:potassium ratio, 
which was approximately 34 in the first three cases 
and significantly higher in the last two cases. There-
fore, it was opted to implement an even higher dose 
reduction in these two cases. The last dog (previously 
treated with FC) was kept on the same starting dosage 
of 2.2 mg/kg, but the dosage interval was increased 
based on serial electrolyte measurements. A fixed in-
terval rate of 64 days was eventually achieved in this 
dog. Two other dogs were started on 1.5 mg/kg. One 
of these dogs had a dose reduction of 10%. The other 
dog (also previously treated with FC) needed an in-
crease of 10%, due to borderline hyperkalemia at day 
ten post injection. 
Further follow-up 
Long-term follow-up was available in four dogs. 
For three of those dogs, the maintenance dosage of 
DOCP varied between 1.2 - 1.8 mg/kg every 28 days. 
The maintenance dosage was reached after two dos-
age adjustments of DOCP in these dogs. For the dog, 
for which interval prolongation was chosen above 
dose reduction, the dosage remained 2.2 mg/kg with a 
fixed extended interval of 64 days. The maintenance 
dosage for prednisolone was 0.08 - 0.28 mg/kg/d PO, 
given once daily in all but one case.
Owner satisfaction and side effects during treatment 
There was a high owner satisfaction rate for the 
treatment of HA with DOCP and prednisolone, based 
on a scale ranging from unsatisfied to very satis-
Table 1. Guidelines for dosage adjustment of Zycortal® according to the manufacturer (Dechra Veterinary Products, 
United Kingdom). Administering the second dose of Zycortal Suspension.
If the day 10  25 days after the first dose, administer
Na+/K+ ratio is:  Zycortal suspension, as follows: 
> 34 Do not Decrease dose to: 2.0 mg/kg
> 32 to 34 administer Decrease dose to: 2.1 mg/kg
27 to 32 dose 2 Continue 2.2 mg/kg
24 to < 27 on day 10 Increase dose to: 2.3 mg/kg 
< 24  Increase dose to: 2.4 mg/kg
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fied, with seven owners being very satisfied and one 
satisfied. For the owners of the two dogs that were 
switched from FC to DOCP, the satisfaction rate was 
notably higher than during the treatment with FC. 
Two dogs, which were immediately started on DOCP, 
experienced polyuria/polydipsia during the treatment 
with DOCP and prednisolone, which resolved after 
a reduction of the prednisolone dose. No adverse ef-
fects attributable to DOCP were noted.
DISCUSSION 
Pure bred, young to middle-aged dogs were over-
represented in this case series, although two dogs 
were older. A female predisposition was not observed 
in the present cases, in contrast to the literature, in 
which a predisposition of 69% has been stated (Feld-
man and Nelson, 2004). This could be due to the small 
number of cases in this retrospective study. 
Most of the cases (63%) were presented as an 
emergency, which could be explained by the dogs 
being selected from a referral university clinic. Most 
dogs (also 63%) showed gastrointestinal signs, and all 
of them presented with anorexia and lethargy, which 
is consistent with the literature. The clinical signs can 
be attributed to the lack of GC, which are vital for 
maintaining the mucosal gastric barrier, blood pres-
sure, blood glucose and body temperature and for 
stress counterregulation. The lack of MC also con-
tributes to clinical signs, as they play a role in water 
homeostasis by promoting renal sodium resorption 
and potassium excretion (Meeking, 2007; Klein and 
Peterson, 2010a; Lathan and Thomspon, 2018). 
Only one dog showed mild regenerative anemia, 
which was most likely due to gastrointestinal bleeding 
since high urea levels were also present. Dehydration 
could have falsely elevated the levels of packed cell 
volume in other cases, masking anemia. The presence 
of dehydration was also evident based on hyperalbu-
minemia in one dog. Dehydration and/or gastrointes-
tinal bleeding could explain the high percentage of 
dogs with increased urea. One dog had unmeasurably 
low blood glucose levels, which could be attributed 
to the lack in GC causing decreased hepatic gluco-
neogenesis and increased insulin sensitivity, com-
bined with the anorexia and vomiting in a toy breed 
dog (Feldman and Nelson, 2004; Klein and Peterson, 
2010a; Lathan and Thompson, 2018). 
All dogs showed abnormal serum electrolyte con-
centrations, which is mainly caused by the lack of 
MC. As described in the literature, serum levels of so-
dium and potassium normalized in most of the pres-
ent cases (7/8) within 24 hours after initiating fluid 
therapy (Feldman and Nelson, 2004; Klein and Peter-
son, 2010b; Lathan and Thompson, 2018). 
The first dog being treated with DOCP followed 
the protocol suggested by the manufacturer (Table 1). 
A starting dosage of 2.2 mg/kg SC was administered 
and the dog was then monitored at day 10, day 25 and 
every five days thereafter until the sodium-to-potas-
sium ratio dropped beneath 32, eventually resulting in 
a fixed interval of 64 days. Gaining experience with 
DOCP, following new guidelines that were discussed 
at the ESVE Post-Congress day, and considering the 
recent literature, all following dogs had a fixed inter-
val of 28 days and two dogs were treated with a lower 
starting dosage of 1.5 mg/kg SC (Bates et al., 2013; 
Lathan and Thompson, 2018). However, one of these 
dogs needed an increase of the dosage at the time of 
the second injection of DOCP. Due to sodium-to-po-
tassium ratios being markedly higher than 34, a dose 
reduction of 20% was performed in two other dogs, 
which is a larger dose reduction than the 5 - 15% dose 
reduction suggested in the literature (Klein and Peter-
son, 2010b; Lathan and Thomspon, 2018). For both 
dogs that were switched from FC to DOCP, FC was 
immediately stopped after injection with DOCP, but 
with a doubling of the previously administered pred-
nisolone dosage. Both dogs were switched to DOCP 
due to insufficient control of the serum electrolyte 
concentrations with FC, whilst already expressing 
GC side effects. After the switch to DOCP, the serum 
electrolyte concentrations normalized rapidly and the 
GC side effects disappeared or improved greatly. 
Baumstark et al. (2014) suggested that DOCP is more 
effective than FC in the treatment of HA. However, 
an earlierer study of Kintzer and Peterson (1997) with 
205 dogs showed no difference regarding efficacy of 
MC replacement and survival time between DOCP 
and FC. 
The starting dosage of prednisolone was notably 
lower in two cases and higher in one case, than the 
dosage of 0.22 - 0.3 mg/kg/day reported in the litera-
ture. However, the two dogs receiving a lower dosage 
were previously treated with FC and GC before the 
first administration of DOCP. In most cases (75%), 
the maintenance dosage of prednisolone was lower 
than the dosage of 0.2 mg/kg/day reported in the lite-
rature (Van Zyl and Hyman, 1994; Kintzer and Peter-
son, 1997; Reusch, 2000; Klein and Peterson, 2010b), 
although a similar dosage has recently been described 
(Lathan and Thompson, 2018).
It should be mentioned that the main limitations of 
this study were the relatively small number of dogs 
and all limitations inherent to the retrospective nature 
of this study.
CONCLUSION
In conclusion, DOCP was successful in maintain-
ing normal serum electrolyte concentrations in eight 
dogs with HA, both in newly diagnosed cases and in 
dogs previously treated with FC. A fixed dosage inter-
val of 28 days was deemed effective and practical. A 
dose reduction of DOCP was possible in 75% of the 
cases at the time of the second injection. In one out of 
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the two cases treated with a lower starting dosage (1.5 
mg/kg), treatment was effective; however, an increase 
in DOCP dosage was necessary for the dog that was 
previously treated with FC.
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